Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

OBJECTIVES: We aimed to assess the expression of the CCL24 chemokine in systemic sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3 axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101...

Descripción completa

Detalles Bibliográficos
Autores principales: Mor, Adi, Segal Salto, Michal, Katav, Avi, Barashi, Neta, Edelshtein, Victoria, Manetti, Mirko, Levi, Yair, George, Jacob, Matucci-Cerinic, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788878/
https://www.ncbi.nlm.nih.gov/pubmed/31129606
http://dx.doi.org/10.1136/annrheumdis-2019-215119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788878/
https://www.ncbi.nlm.nih.gov/pubmed/31129606
http://dx.doi.org/10.1136/annrheumdis-2019-215119

Ejemplares similares